EpiVax will be at the 11th Annual EID and Biodefense Meeting, June 17-19, 2013 at the Almas Temple Club, Washington, DC. Dr. Annie De Groot will be joining a panel of vaccine and influenza experts to discuss pandemic universal influenza vaccines.
Panel: Towards Universal Pandemic Influenza Vaccines
Influenza has officially moved into epidemic status for 2013. Work towards a universal influenza vaccine that can work against not only H3N2 but also the lethal H1N1 and H5N1 continues. This panel will discuss advances being made towards the development of universal pandemic influenza vaccines. They will discuss their funding priorities, efforts to date, the key challenges they face, and what they need from public and private sector partners.
Annie De Groot, M.D., CEO/CSO and Director, EPIVAX INC.
Matthew Lawlor, Ph.D., Project Officer and Interdisciplinary
Scientist, Influenza Division, Biomedical Advanced Research
and Development Authority (BARDA), Office of the Assistant
Secretary for Preparedness and Response (ASPR),
DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS)
Rachelle Salomon, Ph.D., Influenza Vaccines Program Officer,
Respiratory Diseases Branch, Division of Microbiology and
Infectious Diseases (DMID), NATIONAL INSTITUTE OF
ALLERGY AND INFECTIOUS DISEASES (NIAID), NIH, DHHS
James Wilson, M.D., Ph.D., Professor of Pathology and
Laboratory Medicine, UNIVERSITY OF PENNSYLVANIA, GENE
THERAPY PROGRAM, PERELMAN SCHOOL OF MEDICINE
See EpiVax’s H7N9 blog posts and new publication below:
BDA EpiVax, inc.
Email Us Here.